Study of PEP08 for advanced solid tumors with MTAP deletion
Part of Cancer clinical trials.
This trial tests a new drug called PEP08 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). It might be an option if standard treatments no longer work or cause too many side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your tumor must have a missing piece of a gene called MTAP (this is found by testing your tumor tissue).
- You have already tried the usual treatments for your cancer, and they stopped working, or you cannot take them.
- You have at least one tumor that can be measured on scans.
- You must be in fairly good health, able to swallow pills, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called PEP07 for people with advanced or metastatic solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if PEP07 can help shrink or control the cancer.
This trial tests a new drug called BAY 3713372 in people with solid tumors that have a specific genetic change called MTAP deletion. The drug targets a process inside cells that may help stop tumor growth.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
This early-stage trial tests a new drug called HS-10587 in patients whose advanced cancers have a specific genetic feature (MTAP deletion) and have not responded to standard treatments. The drug may help slow or stop cancer growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.